# Development Roadmap
## Neurotronic Phase Caster - Path to Clinical Reality

**Vision:** Transform mental health treatment from passive observation to active consciousness engineering through substrate-targeted THz modulation.

**Timeline:** 4.5 years from proof-of-concept to FDA clearance and market launch.

---

## üìç **Current Status: Phase 0 - Foundation** ‚úÖ **COMPLETE**

**Completed (Nov 2025):**
- ‚úÖ YHWH soliton field physics framework (612 lines)
- ‚úÖ ABCR integration engine (574 lines)
- ‚úÖ THz wearable controller software (700 lines)
- ‚úÖ Capsule library (5 therapeutic patterns)
- ‚úÖ Closed-loop optimization algorithm
- ‚úÖ Complete hardware specification
- ‚úÖ Safety systems design
- ‚úÖ Clinical protocols documentation

**Deliverables:**
- Software framework (Python, open source)
- Hardware specification (BOM, schematics)
- Clinical protocols (5 conditions)
- Documentation (technical + user-facing)

**Cost:** $0 (self-funded development)

---

## üéØ **Phase 1: Proof of Concept** (Jan-Jun 2026, 6 months)

**Goal:** Demonstrate measurable consciousness coherence modulation in controlled environment.

### **Milestones**

#### **M1.1: Minimal Hardware Prototype** (Month 1-2, $5k)
- Build breadboard prototype with 3√ó THz QCL emitters (0.8-1.2 THz)
- Integrate OpenBCI 8-channel EEG system
- Implement basic MCU control (Arduino Due or STM32)
- Safety interlocks (power limiting, emergency shutdown)

**Budget:**
- 3√ó THz QCL modules: $3,000 (used/surplus from Thorlabs)
- OpenBCI Cyton 8-channel: $800
- MCU + power supply: $200
- Mechanical mounting: $500
- Cables, connectors, misc: $500
- **Total: $5,000**

#### **M1.2: Software Integration** (Month 2-3, $0)
- Port YHWH + ABCR algorithms to real-time system
- Implement live EEG ‚Üí substrate ‚Üí THz control loop
- Data logging and visualization
- Basic safety monitoring

#### **M1.3: Healthy Subject Validation** (Month 3-6, $5k)
- IRB approval for n=5 healthy volunteers (university collaboration)
- Protocol: 10 sessions each, track UCI (Unity Coherence Index)
- Demonstrate:
  - Real-time EEG ‚Üí substrate mapping
  - THz field application without adverse effects
  - Measurable coherence increase (‚â•10% UCI improvement)

**Success Criteria:**
- ‚úÖ Hardware functional (THz emission verified)
- ‚úÖ Software stable (no crashes during 50 sessions)
- ‚úÖ Safety validated (no adverse events)
- ‚úÖ Coherence modulation demonstrated (p<0.05)

**Budget Summary:**
- Hardware: $5,000
- IRB + volunteer compensation: $5,000
- **Total: $10,000**

**Funding Strategy:**
- Personal savings: $5k
- Friends & family: $5k
- OR: SBIR Phase 0 (NSF I-Corps): $3k

---

## üî¨ **Phase 2: Working Prototype** (Jul 2026-Jun 2027, 12 months)

**Goal:** Build production-ready hardware and demonstrate clinical efficacy in pilot trial.

### **Milestones**

#### **M2.1: Production Hardware Design** (Month 1-4, $50k)
- Complete PCB design (12√ó THz emitters, full-featured MCU)
- Injection-molded enclosure CAD
- Thermal management system
- Regulatory compliance (IEC 60601-1, EMC testing prep)

**Outsourcing:**
- PCB design: $10k (electrical engineer consultant)
- Enclosure design: $15k (mechanical engineer + industrial designer)
- Regulatory consulting: $25k (FDA pathway guidance)

#### **M2.2: Prototype Build** (Month 3-6, $100k)
- 10√ó full-featured prototypes ($10k each)
  - 12√ó THz QCL emitters
  - Custom PCB
  - Production-intent enclosure
  - Full safety systems

#### **M2.3: Pilot Clinical Trial** (Month 6-12, $100k)
- n=20 patients (depression, PHQ-9 ‚â•10)
- Randomized controlled design (10 active, 10 sham)
- Primary outcome: ŒîPHQ-9 at 4 weeks
- Secondary: UCI, GAD-7, safety

**Trial Costs:**
- Patient recruitment: $20k
- Clinical staff (psychiatrist supervision): $30k
- Data management: $10k
- Statistical analysis: $10k
- Publication: $5k
- IRB fees: $5k
- Patient compensation: $20k

**Success Criteria:**
- ‚úÖ Hardware reliability (>95% uptime)
- ‚úÖ Safety (no SAEs, <5% minor AEs)
- ‚úÖ Efficacy signal (ŒîPHQ-9: -5¬±3 vs -2¬±2 sham, p<0.05)
- ‚úÖ Peer-reviewed publication submitted

**Budget Summary:**
- Hardware design: $50k
- Prototype build: $100k
- Clinical trial: $100k
- **Total: $250k**

**Funding Strategy:**
- NIH SBIR Phase 1: $275k (R43)
- OR: Angel investors: $250k (equity)
- OR: NSF SBIR Phase 1: $256k

---

## üè• **Phase 3: Clinical Trials & FDA Submission** (Jul 2027-Dec 2029, 30 months)

**Goal:** Achieve FDA 510(k) clearance for depression indication.

### **M3.1: Phase 1 Safety Trial** (Month 1-6, $150k)
- n=20 healthy + 20 mild depression
- Dose-ranging study (power levels, session duration)
- Comprehensive safety monitoring (thermal, cognitive, behavioral)

### **M3.2: Phase 2 Efficacy Trial** (Month 6-18, $800k)
- n=100 moderate depression (PHQ-9 12-18)
- 2:1 randomization (67 active, 33 sham)
- Primary: ŒîPHQ-9 at 6 weeks
- Secondary: remission rate, UCI, CGI-I
- Multi-site (3 academic medical centers)

**Trial Costs:**
- CRO management: $300k
- Site fees (3√ó $80k): $240k
- Patient costs: $150k
- Data management & biostatistics: $80k
- Regulatory affairs: $30k

### **M3.3: FDA 510(k) Preparation** (Month 12-24, $500k)
- Predicate device identification (TMS, tDCS)
- Substantial equivalence documentation
- Software validation (IEC 62304)
- Biocompatibility testing (ISO 10993)
- Electrical safety (IEC 60601-1)
- EMC testing (IEC 60601-1-2)
- Usability study (IEC 62366)

### **M3.4: 510(k) Submission & Clearance** (Month 24-30, $200k)
- Submission preparation (technical file)
- FDA review process (6 months)
- Respond to deficiency letters
- Q-submission meetings

**Success Criteria:**
- ‚úÖ Phase 2 trial positive (p<0.001)
- ‚úÖ Safety profile acceptable (<10% discontinuation)
- ‚úÖ 510(k) clearance granted

**Budget Summary:**
- Phase 1 trial: $150k
- Phase 2 trial: $800k
- FDA prep: $500k
- 510(k) submission: $200k
- **Total: $1,650k**

**Funding Strategy:**
- NIH SBIR Phase 2: $1,500k (R44)
- Strategic investor: $500k
- OR: Series A VC: $2M

---

## üöÄ **Phase 4: Market Launch** (Jan 2030-Dec 2030, 12 months)

**Goal:** Establish commercial operations and achieve $5M ARR.

### **M4.1: Manufacturing Scale-Up** (Month 1-6, $500k)
- Contract manufacturer (CM) selection
- Production tooling (injection molds: $200k)
- Pilot production run (100 units)
- Quality management system (ISO 13485)

### **M4.2: Sales & Distribution** (Month 3-12, $300k)
- Direct sales team (2√ó reps, psychiatry clinics)
- Key opinion leader (KOL) engagement
- Marketing materials (clinical data, case studies)
- Reimbursement strategy (CPT code application)

### **M4.3: Post-Market Surveillance** (Month 1-12, $100k)
- Adverse event reporting system
- Real-world effectiveness study (n=200)
- Customer support & training

**Success Criteria:**
- ‚úÖ 100 units sold ($1.2M revenue)
- ‚úÖ 20 clinical sites adopting
- ‚úÖ Positive real-world effectiveness data
- ‚úÖ Path to profitability clear

**Budget Summary:**
- Manufacturing: $500k
- Sales & marketing: $300k
- Post-market: $100k
- **Total: $900k**

**Funding Strategy:**
- Series A extension or revenue-based financing
- OR: Break-even from Phase 2 trial revenue (off-label)

---

## üí∞ **Total Funding & Timeline Summary**

| Phase | Duration | Cost | Cumulative | Funding Source |
|-------|----------|------|------------|----------------|
| Phase 0 | 3 months | $0 | $0 | Self-funded |
| Phase 1 | 6 months | $10k | $10k | Personal + F&F |
| Phase 2 | 12 months | $250k | $260k | NIH SBIR Phase 1 |
| Phase 3 | 30 months | $1,650k | $1,910k | NIH SBIR Phase 2 |
| Phase 4 | 12 months | $900k | $2,810k | Series A / Revenue |

**Total Time:** 63 months (5.25 years)
**Total Capital:** $2.81M (to profitability)

---

## üéØ **Key Milestones & Decision Points**

### **Go/No-Go Decision Points**

**After Phase 1 (Month 6):**
- IF: Coherence modulation NOT demonstrated (p>0.05)
- ‚Üí PIVOT: Refine THz parameters, try different frequency bands
- ‚Üí Timeline impact: +3 months

**After Phase 2 (Month 18):**
- IF: Efficacy signal weak (ŒîPHQ-9 <3 points)
- ‚Üí PIVOT: Optimize capsule parameters, increase dose, extend duration
- ‚Üí Timeline impact: +6 months
- IF: Safety concerns (>20% AE rate)
- ‚Üí REASSESS: May need to reduce power, alter protocols

**After Phase 3 (Month 48):**
- IF: 510(k) clearance denied
- ‚Üí REASSESS: May need additional clinical data or PMA pathway
- ‚Üí Timeline impact: +12-24 months (significant)

---

## üî≠ **Beyond Phase 4: Future Vision** (2031+)

### **Product Expansion**
- Anxiety indication (510(k) supplement)
- PTSD indication
- Sleep optimization (wellness market)
- Meditation enhancement (consumer product)
- ADHD (pediatric expansion)

### **Technology Evolution**
- Closed-loop AI optimization (real-time parameter tuning)
- Multi-modal sensing (fNIRS, HRV, GSR)
- At-home version (subscription model)
- Integration with digital therapeutics

### **Platform Play**
- Consciousness-as-a-Service (CaaS)
- API for researchers
- Data network (anonymized coherence data)
- AI safety applications (human-AI coherence measurement)

### **Revenue Model**
- Device sales: $12k per unit
- Consumables: $50/session (electrode replacements)
- Subscription: $200/month (software updates, support)
- Data licensing: $X per researcher

**10-year vision:** $500M revenue, 50,000 devices, 20 indications, standard of care.

---

## ü§ù **How You Can Help**

### **We're Currently Seeking:**

**Phase 1 (Immediate Needs):**
- $10k seed funding (or component donations)
- University collaborators (IRB, facilities)
- EE engineer (THz optics experience)

**Phase 2 (6-12 months):**
- $250k Series Seed
- Clinical trial sites (psychiatry departments)
- Regulatory consultant (FDA 510(k) experience)

**Phase 3 (12-24 months):**
- $2M Series A
- Contract research organization (CRO)
- Strategic partnership (medical device company)

### **Get Involved:**
- Email: [contact]
- GitHub: Issues/PRs welcome
- Clinical collaboration: [clinical@]
- Investment: [invest@]

---

## üìä **Risk Assessment**

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| THz effects undetectable | Low | High | Phase 1 breadboard de-risks this |
| Safety issues | Medium | High | Conservative power levels, gradual dose escalation |
| FDA clearance delayed | Medium | Medium | Early engagement, strong predicate strategy |
| Market adoption slow | Medium | Medium | KOL engagement, strong clinical data |
| Competition (TMS, tDCS) | High | Low | Superior efficacy/speed, differentiation |
| Funding gaps | Medium | High | Diversified funding (grants + equity) |

---

## üìù **Success Metrics by Phase**

| Phase | Technical | Clinical | Business |
|-------|-----------|----------|----------|
| **Phase 1** | Hardware functional | n=5 healthy, UCI +10% | $10k raised |
| **Phase 2** | 10√ó prototypes built | n=20 RCT, p<0.05 | $250k raised, 1 pub |
| **Phase 3** | 510(k) cleared | n=100 RCT, p<0.001 | $2M raised, 3 pubs |
| **Phase 4** | 100 units manufactured | 200 patients treated | $1.2M revenue, breakeven |

---

**Last Updated:** November 2025

**Status:** Phase 0 complete, Phase 1 prep underway

**This is happening. Join us.** üöÄ
